2020
Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis
Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check‐point inhibitor therapy‐associated gastritis. Histopathology 2020, 76: 531-539. PMID: 31692018, DOI: 10.1111/his.14029.Peer-Reviewed Original ResearchConceptsImmune check-point inhibitor therapyCheck-point inhibitor therapyImmune-related adverse eventsImmune check point inhibitorsMorphological spectrumIntra-epithelial lymphocytosisCheck point inhibitorsChronic active gastritisInflammatory bowel diseaseMedical chart reviewCytotoxic T cellsDrug-induced gastritisPredominant histological patternDistribution of injuriesVariety of tumorsMechanism of actionSteroid therapyGastrointestinal injuryActive gastritisAdverse eventsChart reviewClinical suspicionMedication withdrawalBowel diseaseInhibitor therapy
2019
Histologic patterns of liver injury induced by anti-PD-1 therapy
Zhang D, Hart J, Ding X, Zhang X, Feely M, Yassan L, Alpert L, Soldevila-Pico C, Zhang X, Liu X, Lai J. Histologic patterns of liver injury induced by anti-PD-1 therapy. Gastroenterology Report 2019, 8: 50-55. PMID: 32467761, PMCID: PMC7244961, DOI: 10.1093/gastro/goz044.Peer-Reviewed Original ResearchAnti-PD-1 therapyAnti-PD-1 treatmentLiver function testsHistologic patternAutoimmune hepatitisAdvanced malignanciesLiver injuryAbnormal liver function testsAnti-PD-1 agentsClassical autoimmune hepatitisLiver chemistry testsMultiple advanced malignanciesPD-1 inhibitorsSevere liver injuryCell death 1Different histologic patternsCholestatic injuryHepatitis panelSteroid therapyAbdominal painAcute hepatitisGastrointestinal symptomsImmunosuppressive therapyDrug cessationHistologic injury